These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 23780945)

  • 1. Early progression of diabetic nephropathy correlates with methylglyoxal-derived advanced glycation end products.
    Beisswenger PJ; Howell SK; Russell GB; Miller ME; Rich SS; Mauer M
    Diabetes Care; 2013 Oct; 36(10):3234-9. PubMed ID: 23780945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of diabetic nephropathy from advanced glycation endproducts (AGEs) differs in plasma and urine, and is dependent on the method of preparation.
    Beisswenger PJ; Howell SK; Russell G; Miller ME; Rich SS; Mauer M
    Amino Acids; 2014 Feb; 46(2):311-9. PubMed ID: 24036985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skin advanced glycation end products glucosepane and methylglyoxal hydroimidazolone are independently associated with long-term microvascular complication progression of type 1 diabetes.
    Genuth S; Sun W; Cleary P; Gao X; Sell DR; Lachin J; ; Monnier VM
    Diabetes; 2015 Jan; 64(1):266-78. PubMed ID: 25187362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced Glycation End Products Predict Loss of Renal Function and Correlate With Lesions of Diabetic Kidney Disease in American Indians With Type 2 Diabetes.
    Saulnier PJ; Wheelock KM; Howell S; Weil EJ; Tanamas SK; Knowler WC; Lemley KV; Mauer M; Yee B; Nelson RG; Beisswenger PJ
    Diabetes; 2016 Dec; 65(12):3744-3753. PubMed ID: 27609106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease.
    Tanji N; Markowitz GS; Fu C; Kislinger T; Taguchi A; Pischetsrieder M; Stern D; Schmidt AM; D'Agati VD
    J Am Soc Nephrol; 2000 Sep; 11(9):1656-1666. PubMed ID: 10966490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advanced glycation end products (AGEs) increase renal lipid accumulation: a pathogenic factor of diabetic nephropathy (DN).
    Yuan Y; Sun H; Sun Z
    Lipids Health Dis; 2017 Jun; 16(1):126. PubMed ID: 28659153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Susceptibility to diabetic nephropathy is related to dicarbonyl and oxidative stress.
    Beisswenger PJ; Drummond KS; Nelson RG; Howell SK; Szwergold BS; Mauer M
    Diabetes; 2005 Nov; 54(11):3274-81. PubMed ID: 16249455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvianolic Acid A Protects Against Diabetic Nephropathy through Ameliorating Glomerular Endothelial Dysfunction via Inhibiting AGE-RAGE Signaling.
    Hou B; Qiang G; Zhao Y; Yang X; Chen X; Yan Y; Wang X; Liu C; Zhang L; Du G
    Cell Physiol Biochem; 2017; 44(6):2378-2394. PubMed ID: 29262395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small- and large-fiber neuropathy after 40 years of type 1 diabetes: associations with glycemic control and advanced protein glycation: the Oslo Study.
    Sveen KA; Karimé B; Jørum E; Mellgren SI; Fagerland MW; Monnier VM; Dahl-Jørgensen K; Hanssen KF
    Diabetes Care; 2013 Nov; 36(11):3712-7. PubMed ID: 24026557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating Concentrations of advanced Glycation end Products, Carboxymethyl Lysine and Methylglyoxal are Associated With Renal Function in Individuals With Diabetes.
    Ding L; Hou Y; Liu J; Wang X; Wang Z; Ding W; Zhao K
    J Ren Nutr; 2024 Mar; 34(2):154-160. PubMed ID: 37802233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylglyoxal-hydroimidazolones (MG-Hs) instead of Nɛ-(carboxymethyl)-l-lysine (CML) is the major advanced glycation end-product during drying process in black tea.
    Zhang W; Zhang B; Ye Y; Zhu H
    Food Chem; 2020 Dec; 333():127499. PubMed ID: 32673957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylglyoxal in diabetes: link to treatment, glycaemic control and biomarkers of complications.
    Beisswenger PJ
    Biochem Soc Trans; 2014 Apr; 42(2):450-6. PubMed ID: 24646259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes.
    Genuth S; Sun W; Cleary P; Sell DR; Dahms W; Malone J; Sivitz W; Monnier VM;
    Diabetes; 2005 Nov; 54(11):3103-11. PubMed ID: 16249432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The involvement of advanced glycation endproducts (AGEs) in renal injury of diabetic glomerulosclerosis: association with phenotypic change in renal cells and infiltration of immune cells.
    Mao Y; Ootaka T; Saito T; Sato H; Sato T; Ito S
    Clin Exp Nephrol; 2003 Sep; 7(3):201-9. PubMed ID: 14586716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy.
    Horie K; Miyata T; Maeda K; Miyata S; Sugiyama S; Sakai H; van Ypersole de Strihou C; Monnier VM; Witztum JL; Kurokawa K
    J Clin Invest; 1997 Dec; 100(12):2995-3004. PubMed ID: 9399945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced Glycation End Products, Oxidation Products, and the Extent of Atherosclerosis During the VA Diabetes Trial and Follow-up Study.
    Saremi A; Howell S; Schwenke DC; Bahn G; Beisswenger PJ; Reaven PD;
    Diabetes Care; 2017 Apr; 40(4):591-598. PubMed ID: 28148544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between the expression of advanced glycation end-products (AGE) and the receptor for AGE (RAGE) mRNA in diabetic nephropathy.
    Suzuki D; Toyoda M; Yamamoto N; Miyauchi M; Katoh M; Kimura M; Maruyama M; Honma M; Umezono T; Yagame M
    Intern Med; 2006; 45(7):435-41. PubMed ID: 16679697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultrastructure of nonenzymatically glycated mesangial matrix in diabetic nephropathy.
    Makino H; Shikata K; Hironaka K; Kushiro M; Yamasaki Y; Sugimoto H; Ota Z; Araki N; Horiuchi S
    Kidney Int; 1995 Aug; 48(2):517-26. PubMed ID: 7564121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions.
    Suzuki D; Miyata T; Saotome N; Horie K; Inagi R; Yasuda Y; Uchida K; Izuhara Y; Yagame M; Sakai H; Kurokawa K
    J Am Soc Nephrol; 1999 Apr; 10(4):822-32. PubMed ID: 10203367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roles of advanced glycation end-products in the progression of diabetic nephropathy.
    Makino H; Shikata K; Kushiro M; Hironaka K; Yamasaki Y; Sugimoto H; Ota Z; Araki N; Horiuchi S
    Nephrol Dial Transplant; 1996; 11 Suppl 5():76-80. PubMed ID: 9044313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.